On March 31, 2026 Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, reported upcoming presentations for NXP900 at the upcoming 2026 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Meeting (2026 AACR (Free AACR Whitepaper)), taking place from April 17th to April 22nd in San Diego, CA.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Abstract Title Poster Presentation Details
NXP900, a Phase 1b, first-in-class YES1/SRC inhibitor demonstrates potent synergy with KRAS inhibitors in KRASi sensitive and resistant NSCLC models Session Title
Combination Targeted Therapy

Session Date / Time
April 21st, 2:00 PM – 5:00 PM PT
Resistance to the SFK inhibitor NXP900 in cholangiocarcinoma is characterized by IL13RA2-AKT signaling and can be overcome by combination therapy Session Title
Novel Strategies to Reverse Drug Resistance

Session Date / Time
April 22nd, 9:00 AM – 12:00 PM PT
Targeting myeloid-derived suppressor cells (MDSCs) to restore antitumor immunity in non-small cell lung cancer (NSCLC) via SRC family kinase Inhibition with NXP900 Session Title
Tyrosine Kinase, Phosphatase, and Other Inhibitors

Session Date / Time
April 21st, 2:00 PM – 5:00 PM PT

(Press release, Nuvectis Pharma, MAR 31, 2026, View Source [SID1234664104])